Novo Nordisk

Novo Nordisk A/S is a global pharmaceutical and healthcare company headquartered in Bagsværd, Copenhagen, Denmark. Founded through the merger of two Danish insulin companies originally established in 1923 and 1925, the company today employs approximately 64,974 people and trades on the Copenhagen Stock Exchange (ticker: NOVO B). Its market capitalization notably exceeded the GDP of Denmark's domestic economy in 2023, making it the highest-valued company in Europe.

The company's core focus spans diabetes care, obesity treatment, haemophilia, and growth hormone therapies. Key products include insulin formulations (Tresiba, Levemir, NovoRapid), GLP-1 receptor agonists (Ozempic, Victoza, Wegovy, Rybelsus), haemophilia treatments (NovoSeven), and growth hormone therapies (Norditropin). Semaglutide — sold under multiple brand names for type 2 diabetes and obesity — accounted for nearly 70% of top-line revenue in 2024.

Novo Nordisk holds approximately 55% value market share in the global GLP-1 segment and over 70% share in branded obesity care as of 2024. For fiscal year 2024, the company reported revenue of DKK 290.4 billion (~$42.1 billion USD), a 25% increase year-over-year, and earnings of approximately DKK 101 billion (~$14.5 billion USD).

The company is majority-controlled by Novo Holdings A/S, the investment arm of the Novo Nordisk Foundation, which also funds broader biomedical research. As a dominant player in metabolic disease treatments — an area seeing rapid pharmaceutical innovation — Novo Nordisk is highly attuned to developments in drug delivery, biologics manufacturing, and digital health.